Zealand Pharma presents positive early-stage results for weight-loss candidate
The Danish biotech company is encouraged, although more testing will be needed ”to fully assess the clinical potential” of a new obesity treatment candidate.
by marketwire, translated by daniel pedersen
Zealand Pharma has achieved positive results in a phase 1b trial of amylin analog ZP8396 for the treatment of obesity.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand pharma expects to recover all its SVB deposits
For subscribers
